Europe Markets: JPMorgan says there may be many oil crises this decade as it lifts rating on energy stocks

Globally, it said the key stocks to outperform are Eni, Shell, TotalEnergies, Saudi Aramco
2222,
-0.58%,
Exxon Mobil
XOM,
-1.41%,
Marathon Petroluem
MPC,
+1.38%,
Tenaris
TS,
-2.32%,
Baker Hughes
BKR,
-2.07%,
Cenovus
CVE,
-2.10%,
Prio , PetroChina
601857,
+1.50%,
Beach Energy
BPT,
+0.31%
and Ampol
ALD,
+2.11%.

“Dear generalists, put your seatbelts on,” said analysts led by Christyan Malek. “While we believe the sector is in a structural up-cycle and oil should normalize higher, we expect prices and by extension energy equities to trade in a wider range, discounting an effective higher weighted average cost of capital associated with elevated price volatility and concerns around ESG/peak demand.”

The analysts do not share the peak demand fears, at least on its investment horizon that runs through 2030, saying the clean energy system is not mature enough to capture and distribute to end customers. “As a result, this places greater pressure on traditional fuels to fill the gap and meet rising EM-led demand growth. However, without increasing oil and gas capex, we risk energy deficits and acute inflation across the commodities complex.”

“This may lead to multiple oil-led energy crises in this decade, potentially much more severe than the gas crisis seen in Europe in 2022. Moreover, it serves to position OPEC firmly at the steering wheel of the global oil market, to take greater share of demand growth, while helping mitigate sharp price moves in either direction.”

One interesting note is that the analysts do not find oil prices in the $100-to-$120 range to be demand destructive, as it would still imply oil’s share of the world economy below 4%.

Friday saw a catching down of European stocks to the sharp decline on Thursday on Wall Street, even though U.S. stock futures pointed to a stronger start.

The U.K. FTSE 100
UK:UKX
was flat while the German DAX
DX:DAX
fell 0.5% and the French CAC 40
FR:PX1
lost 0.9%.

Ubisoft Entertainment shares
UBI,
+3.58%
rose 4% after the U.K. competition regulator provisionally blessed the Microsoft-Activision deal that would see the French video games maker get cloud rights to Activision
ATVI,
-0.23%
games.

AstraZeneca stock
AZN,
+2.35%
added 2% as it and partner Daiichi Sankyo said a Phase III trial of a breast cancer drug showed statistically significant progression-free survival benefit. “This was another pivotal readout for [datopotamab deruxtecan] and could reinvigorate sentiment about this drugs broader potential to replace systemic chemotherapy across a range cancers whilst also providing another important read on safety,” said Dr. Sean Conroy, an analyst at Shore Capital.